Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma


MicroRNAs (miRNAs) belong to a recently discovered class of small RNA molecules that regulate gene expression at the post-transcriptional level. miRNAs have crucial functions in the development and establishment of cell identity, and aberrant metabolism or expression of miRNAs has been linked to human diseases, including cancer1. Components of the miRNA machinery and miRNAs themselves are involved in many cellular processes that are altered in cancer, such as differentiation, proliferation and apoptosis. Some miRNAs, referred to as oncomiRs2, show differential expression levels in cancer and are able to affect cellular transformation, carcinogenesis and metastasis, acting either as oncogenes or tumour suppressors. The phenomenon of ‘oncogene addiction’ reveals that despite the multistep nature of tumorigenesis, targeting of certain single oncogenes can have therapeutic value3,4, and the possibility of oncomiR addiction has been proposed but never demonstrated3. MicroRNA-21 (miR-21) is a unique miRNA in that it is overexpressed in most tumour types analysed so far. Despite great interest in miR-21, most of the data implicating it in cancer have been obtained through miRNA profiling and limited in vitro functional assays. To explore the role of miR-21 in cancer in vivo, we used Cre and Tet-off technologies to generate mice conditionally expressing miR-21. Here we show that overexpression of miR-21 leads to a pre-B malignant lymphoid-like phenotype, demonstrating that mir-21 is a genuine oncogene. When miR-21 was inactivated, the tumours regressed completely in a few days, partly as a result of apoptosis. These results demonstrate that tumours can become addicted to oncomiRs and support efforts to treat human cancers through pharmacological inactivation of miRNAs such as miR-21.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1: mir-21 LSL-Tetoff transgenic mice overexpress miR-21.
Figure 2: Lymphoma in NesCre8, mir-21 LSL-Tetoff mice.
Figure 3: Tumour dependence on miR-21 overexpression.
Figure 4: Tumour regression is partly due to apoptosis.


  1. Medina, P. P. & Slack, F. J. microRNAs and cancer: an overview. Cell Cycle 7, 2485–2492 (2008)

    CAS  Google Scholar 

  2. Esquela-Kerscher, A. & Slack, F. J. Oncomirs—microRNAs with a role in cancer. Nature Rev. Cancer 6, 259–269 (2006)

    CAS  Google Scholar 

  3. Sharma, S. V. & Settleman, J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214–3231 (2007)

    CAS  Google Scholar 

  4. Weinstein, I. B. & Joe, A. Oncogene addiction. Cancer Res. 68, 3077–3080 (2008)

    CAS  Google Scholar 

  5. Costinean, S. et al. Ship and C/ebp-β are targeted by miR-155 in B cells of Eμ-miR-155 transgenic mice. Blood 117, 1374–1382 (2009)

    Google Scholar 

  6. Si, M. L. et al. miR-21-mediated tumor growth. Oncogene 26, 2799–2803 (2007)

    CAS  Google Scholar 

  7. Iorio, M. V. et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65, 7065–7070 (2005)

    CAS  Google Scholar 

  8. Chan, J. A., Krichevsky, A. M. & Kosik, K. S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65, 6029–6033 (2005)

    CAS  Google Scholar 

  9. Schetter, A. J. et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. J. Am. Med. Assoc. 299, 425–436 (2008)

    CAS  Google Scholar 

  10. Volinia, S. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103, 2257–2261 (2006)

    CAS  Google Scholar 

  11. Fulci, V. et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109, 4944–4951 (2007)

    CAS  Google Scholar 

  12. Lawrie, C. H. et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int. J. Cancer 121, 1156–1161 (2007)

    CAS  Google Scholar 

  13. Jongen-Lavrencic, M., Sun, S. M., Dijkstra, M. K., Valk, P. J. & Lowenberg, B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111, 5078–5085 (2008)

    CAS  Google Scholar 

  14. Navarro, A. et al. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood 111, 2825–2832 (2008)

    CAS  Google Scholar 

  15. Mao, J., Barrow, J., McMahon, J., Vaughan, J. & McMahon, A. P. An ES cell system for rapid, spatial and temporal analysis of gene function in vitro and in vivo . Nucleic Acids Res. 33, e155 (2005)

    Google Scholar 

  16. Zambrowicz, B. P. et al. Disruption of overlapping transcripts in the ROSA βgeo 26 gene trap strain leads to widespread expression of β-galactosidase in mouse embryos and hematopoietic cells. Proc. Natl Acad. Sci. USA 94, 3789–3794 (1997)

    CAS  Google Scholar 

  17. Petersen, P. H., Zou, K., Hwang, J. K., Jan, Y. N. & Zhong, W. Progenitor cell maintenance requires numb and numblike during mouse neurogenesis. Nature 419, 929–934 (2002)

    CAS  Google Scholar 

  18. Morse, H. C. et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 100, 246–258 (2002)

    CAS  Google Scholar 

  19. Pennycook, J. L., Chang, Y., Celler, J., Phillips, R. A. & Wu, G. E. High frequency of normal DJH joints in B cell progenitors in severe combined immunodeficiency mice. J. Exp. Med. 178, 1007–1016 (1993)

    CAS  Google Scholar 

  20. Li, J. et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin. Cancer Res. 15, 3998–4008 (2009)

    CAS  Google Scholar 

  21. Seike, M. et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc. Natl Acad. Sci. USA 106, 12085–12090 (2009)

    CAS  Google Scholar 

  22. Imai, Y. et al. Caspase inhibitor, ZVAD-fmk, facilitates engraftment of donor hematopoietic stem cells in intra-bone marrow–bone marrow transplantation. Stem Cells Dev. 10.1089/scd.2009.0251

  23. Felsher, D. W. & Bishop, J. M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199–207 (1999)

    CAS  Google Scholar 

  24. Yokoyama, K. & Imamoto, F. Transcriptional control of the endogenous MYC protooncogene by antisense RNA. Proc. Natl Acad. Sci. USA 84, 7363–7367 (1987)

    CAS  Google Scholar 

  25. Li, T., Li, D., Sha, J., Sun, P. & Huang, Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem. Biophys. Res. Commun. 383, 280–285 (2009)

    CAS  Google Scholar 

  26. Zhu, S. et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 18, 350–359 (2008)

    CAS  Google Scholar 

  27. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000)

    CAS  Google Scholar 

  28. Huettner, C. S., Zhang, P., Van Etten, R. A. & Tenen, D. G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genet. 24, 57–60 (2000)

    CAS  Google Scholar 

  29. Weinstein, I. B. & Joe, A. K. Mechanisms of disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nature Clin. Pract. Oncol. 3, 448–457 (2006)

    CAS  Google Scholar 

  30. Koopman, G. et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84, 1415–1420 (1994)

    CAS  Google Scholar 

Download references


We thank X. Liang for help in mouse colony maintenance and genotyping; D. Scavone and T. Nottoli for assistance with generating the transgenic mice; Yale rodent care staff M. Bonk, K. Mclaughlin, J. Graham, D. Clark; C. Zeiss, L. Johnson and G. Terwilliger for help with the necropsy/pathological analysis; and I. Babar, P. Trang and J. Sklar for critical reading of the manuscript. P.P.M. is the recipient of a Postdoctoral Fellowship from Hope Funds for Cancer Research. This work was funded by a grant from the James McDonnell Foundation to F.J.S. and J. B. Weidhaas, and a pilot grant from the Yale Comprehensive Cancer Center.

Author information

Authors and Affiliations



F.J.S. designed the project and supervised all the experiments. F.J.S. and M.N. designed the genetically engineered miR-21 mouse. M.N. constructed and tested the mir-21 vector. P.P.M. performed all the phenotyping experiments in the manuscript. F.J.S. and P.P.M. designed the phenotyping experiments and wrote the manuscript.

Corresponding author

Correspondence to Frank J. Slack.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Figures

This file contains Supplementary Figures 1-22 with legends. (PDF 13808 kb)

Supplementary Movie 1

This movie shows NesCre8, mir-21LSL-Tetoff mouse phenotype. Seconds 0-4: The mouse situated at 30° suffers from a conspicuous axillary lymphadenopathy and incipient paraparesis. Seconds 5-7: The mouse situated at 30° suffers from a conspicuous paraparesis. (MOV 8928 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Medina, P., Nolde, M. & Slack, F. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 467, 86–90 (2010).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing